Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 69Fluorouracil 44pembrolizumab 43Oxaliplatin 42Capecitabine 40Bevacizumab 37Leucovorin 36Irinotecan 31Cisplatin 27Nivolumab 24Paclitaxel 21Cetuximab 21Panitumumab 20130-nm albumin-bound paclitaxel 20Sorafenib 18Albumin-Bound Paclitaxel 18Drug Therapy 15Docetaxel 15Cyclophosphamide 15Radiotherapy 14Blood Specimen Collection 14IFL protocol 12atezolizumab 11Exercise 11Taxes 10budigalimab 9Erlotinib Hydrochloride 9trametinib 8Folfox protocol 8Carboplatin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × CLR1404 × Gastrointestinal × Clear all
NCT01495663 2015-02-26

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cellectar Biosciences, Inc.

Phase 1 Completed
12 enrolled
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡